A randomised interventional trial of  -3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus

2008 ◽  
Vol 67 (6) ◽  
pp. 841-848 ◽  
Author(s):  
S A Wright ◽  
F M O'Prey ◽  
M T McHenry ◽  
W J Leahey ◽  
A B Devine ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Fatty Acids ◽  
Endothelial Function ◽  
Polyunsaturated Fatty Acids ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Interventional Trial

The effect of Omega-3 fatty acid supplementation in systemic lupus erythematosus patients: A systematic review

Lupus ◽  
2022 ◽  
pp. 096120332110679
Author(s):  
Nina Ramessar ◽  
Abhilasha Borad ◽  
Naomi Schlesinger
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Fatty Acids ◽  
Fatty Acid ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Omega 3 ◽  
Systemic Lupus ◽  
Fatty Acid Supplementation ◽  
Acid Supplementation ◽  
Omega 3 Fatty Acid

Objective Many rheumatologists are inundated with questions about what “natural remedies” and “anti-autoimmune diets” exist for decreasing Systemic Lupus Erythematosus (SLE) disease activity. Over the last three decades, there has been an abundance of data from several different trials about omega-3 fatty acids sourced from fish oil, but the findings have been contradictory. This review seeks to present this data so that evidence-based recommendations can be given to patients, supporting the use of an adjuvant regimen with their present immunosuppression. Methods A literature search was conducted using the PubMed, Google Scholar, MEDLINE, and Scopus electronic databases to retrieve relevant articles for this review. Trials conducted on human subjects with SLE with full publications in English were included from 1 January 1980 to 1 April 2021. The impact of fish oil-derived omega-3 fatty acid supplementation on specific clinical features, the innate and adaptive immune response, biomarkers, and disease activity measures were assessed. The initial search yielded 7519 articles, but only 13 met our criteria and were eligible for this review. Results Data from thirteen articles were assessed. Ten trials assessed disease activity as an outcome, with eight trials demonstrating an improvement in patients in the omega-3 fatty acid group as assessed by a validated clinical tool or individual patient criteria. There was a significant improvement in Systemic Lupus Activity Measure-Revised (SLAM-R) scores at week 12 ( p = .009) and week 24 ( p < .001). Additionally, a reduction of urinary 8-isoprostane, a non-invasive marker of disease activity, was observed. There was no treatment benefit seen with respect to renal parameters such as serum creatinine or 24-hour urine protein; or systemic parameters such as C3, C4, or anti-double stranded DNA (anti-dsDNA) levels regardless of the dose of the omega-3 LUPUS fatty acids or duration of the trial. Conclusion While there is conflicting evidence about the benefits of omega-3 fatty acid supplementation on SLE disease activity, specific measures have demonstrated benefits. Current data show that there is a potential benefit on disease activity as demonstrated by SLAM-R, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and British Isles Lupus Assessment Group (BILAG) scores and plasma membrane arachidonic acid composition and urinary 8-isoprostane levels, with minimal adverse events.

scholarly journals AB0079 ENDOTHELIAL FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: IMPACT OF CAFFEINE CONSUMPTION ON ENDOTHELIAL PROGENITOR CELLS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1069.2-1069
Author(s):  
V. Orefice ◽  
F. Ceccarelli ◽  
C. Barbati ◽  
E. Putro ◽  
C. Pirone ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Endothelial Function ◽  
Disease Activity ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Lupus Erythematosus ◽  
Caffeine Intake ◽  
Systemic Lupus ◽  
Endothelial Progenitor ◽  
History Of

Background:As widely demonstrated, circulating endothelial progenitor cells (EPCs) could be considered biomarkers of endothelial dysfunction. Their frequency and function varied in systemic lupus erythematosus (SLE) patients, with a significant association with subclinical atherosclerosis1. Caffeine, one of the most widely consumed products in the world, seems to interact with multiple components of the immune system by acting as a non-specific phosphodiesterase inhibitor2. In terms of cardiovascular disease (CVD), data from the literature showed a U-shaped association between habitual coffee intake and CVD3. In this view, Spyridopoulos et al. demonstrated a significant improvement in mature endothelial cells and EPCs migration in relation to coffee consumption in coronary artery disease both in mouse models and in patients4. Finally, caffeine seems to play a positive effect on SLE disease activity status, as demonstrated by the inverse association between its intake and SLE Disease Activity Index 2000 (SLEDAI-2K) and the serum levels of inflammatory cytokines5. At the best of our knowledge, there are no data about the effect of caffeine on cardiovascular risk in SLE patients.Objectives:The aim of this study was to evaluate the possible role of caffeine intake on endothelial function in SLE patients, by evaluating its effect on circulating EPCs.Methods:We performed a cross-sectional study enrolling SLE patients, fulfilling the revised 1997 ACR criteria. According with the protocol study, we excluded patients with history of smoking, CVD, chronic kidney failure, dyslipidaemia, and/or diabetes. At recruitment, the clinical and laboratory data were collected and disease activity was assessed using the SLEDAI-2k. Caffeine intake was evaluated using a 7-day food frequency questionnaire, previously employed in SLE cohort5. At the end of questionnaire filling, blood samples were collected. EPCs were isolated from peripheral blood mononuclear cells (PBMC) by a flow cytometry analysis and they were defined as early EPCs CD34+KDR+CD133+ cells and late EPCs CD34+KDR+CD133-, expressed as a percentage within the lymphocyte gate.Results:We enrolled 19 patients (F:M 18:1, median age 45 years, IQR 15; median disease duration 240 months, IQR 168). In this cohort, we observed a mean±SD SLEDAI-2k value of 1.3±3.3 and the most frequent disease-related feature was joint involvement (73.7%). Concerning treatment at the time of enrolment, the majority of patients were receiving treatment with hydroxychloroquine (78.9%) and seven with glucocorticoids (36.8%). The median intake of caffeine was 163 mg/day (IQR 138) and we used this value as cut-off to categorize SLE patients in 2 groups: group 1 (N=10, caffeine intake ≤ 163 mg/day) and group 2 (N=9, caffeine intake > 163 mg/day). Patients with less intake of caffeine showed a significantly more frequent history of lupus nephritis (p=0.03), haematological manifestations (p=0.0003) and anti-dsDNA positivity (p=0.0003). Moving on EPCs, a positive correlation between caffeine intake and EPCs percentage was observed (p=0.04, r=0.4) (Figure 1A). Moreover, patients with more caffeine intake showed higher levels of early EPCs (p=0.02) (Figure 1B).Conclusion:This is the first report analysing the impact of caffeine on EPCs frequency in SLE patients. We found a positive correlation between its intake and both early and late EPCs percentage, suggesting a caffeine influence on endothelial function in SLE patients. Nonetheless, these results support the possible impact of dietary habits on autoimmune diseases.References:[1]Westerweel et al. Ann Rheum Dis 2007.[2]Aronsen et al. Europ Joul of Pharm 2014.[3]Ding et al. Circulation 2015.[4]Spyridopoulos et al. Art. Thromb Vasc Biol. 2008.[5]Orefice et al. Lupus 2020.Disclosure of Interests:None declared

Effect of omega-3 fatty acids on systemic lupus erythematosus disease activity: A systematic review and meta-analysis

2020 ◽  
Vol 19 (12) ◽  
pp. 102688
Author(s):  
Alí Duarte-García ◽  
Elena Myasoedova ◽  
Paras Karmacharya ◽  
Mehmet Hocaoğlu ◽  
M. Hassan Murad ◽  
...  
Keyword(s):  
Systematic Review ◽  
Systemic Lupus Erythematosus ◽  
Fatty Acids ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Meta Analysis ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Systemic Lupus Erythematosus Disease ◽  
Systemic Lupus
Sign in / Sign up

Export Citation Format

Share Document